I almost forgot about this one. This one looks like a medium (1/2 year) to long term (1 year+) hold for me:
SCLN (8 15/16) Sciclone Pharmaceuticals.
SciClone is a global biopharmaceutical company that acquires, develops and commercializes specialist-oriented drugs for treating chronic and life-threatening diseases. For the 9 months ended 9/99, revenues totalled $6.4M, up from $2.5M. Net loss applicable to Common decreased 67% to $4.9M. Results reflect increased sales of ZADAXIN due to greater distribution in China, partially offset by increasedpayroll and advertising expenses.
REVENUE
Quarters 1996 1997 1998 1999
MAR 126 671 654 1,777
JUN 122 623 801 2,108
SEP 152 673 1,006 2,513
DEC 303 256 1,264 2,999*
Totals 703 2,223 3,725 9,397
MKT cap ~ 223 million
Zadaxin should pull in good revenue for them.
I'm not in yet, but look to get in tomorrow morning unless it breaks down. I'll add it to the portfolio.
siliconinvestor.com
JJJ |
